Compare GameStop Corp. (GME) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GameStop Corp. vs Recursion Pharmaceuticals Inc — how do they compare? GameStop Corp. trades at $18.46 (market cap $8.44B), while Recursion Pharmaceuticals Inc trades at $3.31 (market cap $1.81B). The key difference: GameStop Corp. is far larger — about 4.7× Recursion Pharmaceuticals Inc's market cap, and Recursion Pharmaceuticals Inc is trading nearer its 52-week high, GameStop Corp. nearer its low. Which is the better fit depends on your goals.
| GME | RXRX | |
|---|---|---|
Market Cap | $8.44B | $1.81B |
Sector | Consumer Cyclical | Health |
52-Week High | $27.69 | $6.79 |
52-Week Low | $18.79 | $2.84 |
Enterprise Value | $4.42B | $1.33B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GME trades at $18.79, down 1.93% today, with a bearish technical signal from moving averages but oversold RSI readings. Recent earnings beats and a net income margin of 20.45% highlight improving profitability, though revenue declined to $3.82B in 2025. News indicates potential shifts in the proposed eBay acquisition strategy, moving toward a partnership instead of a full takeover.
The outlook is mixed: strong earnings momentum and low debt-to-asset ratio of 0.28 support upside, but bearish analyst consensus (16.67% buy) and revenue contraction pose risks. Investors face dilution concerns from a $1.4B debt-for-stock swap, while collectibles growth offers opportunity.
RXRX trades at $3.33, up 1.22% in the last session, with a bearish technical signal and RSI near overbought levels. The company reported a Q2 2026 earnings miss with revenue of $54M and a net loss of $519M, reflecting a net margin of -961.97%. Recent news highlights participation in investor conferences and a Genentech partnership advancement, but competitive pressures and slow revenue growth remain concerns.
Outlook is cautious due to persistent losses and high cash burn, though partnerships provide some validation. Risks include execution challenges in drug discovery and reliance on milestone payments. Analysts show a mixed stance with 40% buy ratings, but the stock faces headwinds from weak profitability and bearish technical trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GameStop Corp.
Global Market Group Ltd. operates an Internet website that connects Chinese manufacturers with international buyers. The Company's customers can post company profiles and product information in standardized formats; post product listings; and trade leads.
Read more on GME →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
